Reddit 
X.com 
Facebook 
Pinterest 
Threads 
Bluesky 
WhatsApp 
Telegram 
Messenger 
Email Uğur Şahin & Özlem Türeci
Co-founding BioNTech and developing the first approved mRNA COVID-19 vaccine
How the husband-and-wife scientists behind BioNTech spent two decades on cancer immunotherapy — then used that platform to deliver a COVID-19 vaccine in months.
Uğur Şahin and Özlem Türeci are usually introduced as “the couple behind the COVID vaccine.” The more instructive story is the twenty years before 2020, because the speed everyone remembers was the payoff of a long, patient platform bet.
How they innovate
The pair — physicians and immunologists who met in the 1990s — built BioNTech around mRNA, a then-unfashionable idea: instead of manufacturing a drug, give the body the instructions to make its own therapeutic protein. For years the target was personalized cancer immunotherapy, an extraordinarily hard problem with no guaranteed payday.
When SARS-CoV-2’s genome was published in January 2020, that platform turned out to be exactly the right tool. Şahin sketched vaccine candidates within days (“Project Lightspeed”); the partnership with Pfizer supplied global trials and manufacturing. The vaccine that normally takes a decade arrived in under a year — not because corners were cut, but because the underlying technology had been refined for two.
Their approach is a master class in platform thinking:
- Bet on a capability, not a product. A flexible mRNA platform could be re-aimed at a new target almost overnight.
- Pair deep science with the right partner to cover scale you don’t have.
- Stay close to the bench. Both remained working scientists, not just executives.
What guides them
A patient, mission-first temperament. They are famously modest — reportedly cycling to work and reinvesting returns into research rather than lifestyle. The vaccine was treated less as a windfall than as proof that the cancer platform they had always believed in could work at scale.
What makes them effective
Complementary strengths and total alignment: Şahin often described as the systems-level strategist, Türeci as the translational-medicine and clinical lead. Two decades of working together let them move fast under pressure without relitigating fundamentals — and gave them a platform ready for a moment no one could have scheduled.
Incidental facts
- Both are children of Turkish immigrants to Germany; Şahin’s father worked at a Ford factory in Cologne.
- Founded BioNTech in Mainz in 2008; it was largely unknown to the public until 2020.
- They have continued to push the original goal: mRNA-based cancer vaccines now in clinical trials.